Medigen Biotechnology (3176) - Total Liabilities

Latest total liabilities as of September 2025: NT$1.45 Billion TWD

Based on the latest financial reports, Medigen Biotechnology (3176) has total liabilities worth NT$1.45 Billion TWD as of September 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Medigen Biotechnology - Total Liabilities Trend (2003–2024)

This chart illustrates how Medigen Biotechnology's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Medigen Biotechnology Competitors by Total Liabilities

The table below lists competitors of Medigen Biotechnology ranked by their total liabilities.

Liability Composition Analysis (2003–2024)

This chart breaks down Medigen Biotechnology's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Medigen Biotechnology's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Medigen Biotechnology (2003–2024)

The table below shows the annual total liabilities of Medigen Biotechnology from 2003 to 2024.